Replies to post #150886 on Biotech Values

[mcbio]

The latest info on Presidio’s PPI-668 (an NS5A inhibitor) are the 3-day monotherapy data reported in Jun 2012 (#msg-76993511).

Not sure off-hand how that compares to NS5A 3-day data from others.

All told, therefore, combining these two HCV drugs does not exactly seem like a winning formula for commercial success.

What's that saying of yours? Something about two turkeys? ; )

[jq1234]

I continue to maintain that BCRX’s nucleoside drug is based on obsolete and discredited technology

BCRX Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

The FDA indicated concerns regarding the preclinical toxicity profile of BCX5191 at exposure levels that they believe are likely to be necessary to reduce viral load in patients infected with the hepatitis C virus (HCV). Patient safety remains BioCryst's highest priority. BioCryst continues to believe that BCX5191 may be distinct from other Nucs in exhibiting antiviral potency in man at significantly lower doses than other Nucs in development based on preclinical results, and will therefore conduct additional preclinical studies to determine if low doses—i.e. doses that are not associated with toxicity in animals—exhibit meaningful viral load reductions in HCV infected animals. BioCryst will then determine whether to continue development of BCX5191, based on the results of these studies.

BioCryst agrees with the FDA's cautious approach to the development of nucleoside and nucleotide inhibitors for HCV. Further, BioCryst believes that the recent occurrence of serious adverse events in HCV patients treated with BMS-986094, a nucleotide prodrug previously under clinical development by Bristol-Myers Squibb, has heightened safety concerns regarding this class of HCV inhibitors. FDA has previously placed clinical holds on other nucleotides under development.

http://investor.shareholder.com/biocryst/releaseDetail.cfm?ReleaseID=717319